- A High-Impact Research for Lombardy’s Healthcare Innovation
- A Network of Excellence in Research, Clinical Science and Technology
- Digital Twin and Artificial Intelligence for the Medicine of the Future
- A Project Aligned with Regione Lombardia’s Smart Specialization Strategy (S3)
Milan, 2025 – synbrAIn, an Italian company specializing in the development of ethical and human-centered Artificial Intelligence solutions for Digital Healthcare, has been awarded funding under Regione Lombardia’s “Collabora & Innova” call, part of the Regional Program FESR 2021-2027 – Axis 1 “A more competitive and intelligent Europe”.
The initiative falls within Specific Objective 1.1: “Develop and strengthen research and innovation capacities and the adoption of advanced technologies” and Action 1.1.3: “Support for the implementation of complex research, development and innovation projects.”
A High-Impact Research for Lombardy’s Healthcare Innovation
The project, entitled COPAILOT (COllaborative Platform of Artificial Intelligence Learning from Omics Technologies), aims to develop a digital collaborative platform prototype based on the Digital Twin concept, applied to personalized predictive medicine.
With a total project value of 1.183,278.52€ and funding of 709,967.11€ awarded to synbrAIn, COPAILOT represents a strategic step toward creating a digital ecosystem capable of integreting clinical and omic data from multiple research centers and healthcare facilities, enhancing collaboration between healthcare professionals and advanced AI systems.
The project’s goal is to create a digital replica of the patient, a digital twin, able to simulate, in real time, clinical phenotypes, disease progression, and therapeutic responses, thereby improving the precision of medical decisions and paving the way for truly personalized medicine.
A Network of Excellence in Research, Clinical Science and Technology
The COPAILOT project will be developed through a strong collaboration between synbrAIn and a network of leading national research and clinical partners, including:
- IRCCS Galeazzo;
- Centro Diagnostico Italiano (CDI);
- Fondazione IRCCS Istituto Nazionale dei Tumori;
- Istituti Clinici Scientifici Maugeri;
- Fondazione IRCCS Policlinico San Matteo.
Alongside these prestigious institutions, the partnership includes highly specialized and innovative technology SMEs such as Deeptrace Technologies S.r.l., Mia S.r.l, and synbrAIn S.r.l.
Digital Twin and Artificial Intelligence for the Medicine of the Future
At the heart of COPAILOT lies the creation of personalized predictive models that assist physicians in identifying the most effective treatments, minimizing clinical risks, and increasing therapeutic success rates.
The platform will employ a low-environmental-impact system for data integration and visualization, including multifactorial risk prediction models that promote real-time cooperation between physicians and AI.
The main application areas include:
- oncology:neuro-oncology, lung, breast, prostate, and gynecological cancers;
- musculoskeletal diseases;
- cardiovascular and respiratory conditions.
Through real-time predictive simulation, COPAILOT offers a completely new perspective for managing chronic and complex diseases, enabling the transition toward a more efficient, sustainable, and personalized healthcare system.
A Project Aligned with Regione Lombardia’s Smart Specialization Strategy (S3)
COPAILOT perfectly aligns with the Smart Specialization Strategy (S3) of Regione Lombardia, promoting the growth and consolidation of the regional research and innovation ecosystem.
Through collaboration among companies, research centers, and clinical institutions, the project aims to:
- strengthen the competitiveness of Lombardy’s healthcare system;
- optimize diagnostic and therapeutic pathways;
- promote cost reduction and sustainability;
- ensure full compliance with data protection and privacy regulations.
In the long term, COPAILOT has the potential to be scaled nationally and across Europe, fostering deeper integration between clinical research, artificial intelligence, and personalized medicine.
